India and China Emerging as Biotech API Hubs
In the Asia-Pacific regions, India and China are expected to emerge as biotech API hubs with robust developments, says RNCOS.
(prHWY.com) August 6, 2012 - NOIDA, India -- According to a new research report by RNCOS entitled, "Global Biotech API Market Analysis", the Asia-Pacific regions are emerging fast in the global API industry, primarily due to their significant production of biogenerics. Particularly, India and China are emerging as global hubs in the global API market. During the four year period (2007-2011), the market in Asia Pacific grew by around 21.7%, per annum with India and China individually growing at the rate of 30-35%. The availability of cheap labor, affordable infrastructure, and robustly developing biotechnology and pharma sectors has a major role to play in the growth of these economies.

Biotech APIs are growing robustly due to their high utility and their effectiveness in treating complex diseases. Currently, innovator APIs represent the major chunk of the biotech APIs industry but the growth prospects of biogeneric APIs is much brighter in the future. Geographically, the US represents the largest manufacturer of biotech APIs in the world. However, many smaller countries are emerging as promising biotech API developers and bigger names in the industry are increasingly employing outsourcing strategies to them for developing biotech APIs. According to the latest report by RNCOS, "Global Biotech API Market Analysis", the biotech API market is expected to grow at a CAGR of around 15% from 2012-2015.

The report, which is spread in over 55 pages, provides an analysis of the global API and biotech API market. It provides a global break up of branded and generic API's and synthetic and biotech API's. Further, the biotech API market has been covered along with its major market segments. The geographic break-up provides an analysis on major geographies and untapped markets. The current and future forecasts for the API market have been presented to provide the market progress in the coming years along with expected growth in the overall industry. Regulatory scenario analysis has also been provided for a holistic understanding of the industry requirements. Major focus has been laid on the key competitor assessment to present a meaningful description of the biotech API business along with an analysis on their strengths and weaknesses.

For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM424.htm

Some of our Related Reports are:

- EPO Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM392.htm)
- G-CSF Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM393.htm)
- HGH Biosimilars Market Forecast to 2015 (http://www.rncos.com/Report/IM394.htm)
- Global RNAi Market Analysis (http://www.rncos.com/Report/IM329.htm)
- Global Gene Therapy Market Analysis (http://www.rncos.com/Report/IM282.htm)

Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm

About RNCOS

RNCOS specializes in Industry intelligence and creative solutions for contemporary business segments. Our professionals analyze the industry and its various components, with a comprehensive study of the changing market behavior. Our accuracy and data precision proves beneficial in terms of pricing and time management that assist the intending consultants in meeting their objectives in a cost-effective and timely manner.

###

Web Site: http://www.rncos.com
Contact Information
B-129, Sector 6 Noida - 201301
91-120-4224-700
91-120-4224-707